secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001558370-23-013237
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure Q2 net loss $17.9M; cash $130.6M; Phase 1b data expected Q4 2023
-------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $130.6M as of June 30, 2023, down from $159.9M at Dec 31, 2022.
- Net loss of $17.9M for Q2 2023, flat versus Q2 2022; R&D expense $13.4M, G&A $5.7M.
- Phase 1b data for NC410, NC762 update, and NC525 Phase 1a update all expected in Q4 2023.
- Existing cash expected to fund operations into mid-2025.
- NC318 data from Yale Cancer Center to be presented at WCLC in September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023013237/0001558370-23-013237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837023013237/nxtc-20230803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer